Depo-Provera 500mg vial 3,3ml

Composition

1 ml contains methylprednisolone acetate 150 mg, 1 vial of 3.3 ml - 500 mg.

Packaging

1 bottle of 3.3 ml.

Mechanism of action

Depo Provera is an antitumor drug, the gestagen is a depot form.

Does not possess androgenic and estrogenic activity. Depo-Provera inhibits the secretion of gonadotropic hormones (especially LH). In small doses, inhibits ovulation. It has an inhibitory effect on the changes necessary to prepare the endometrium for implantation of a fertilized egg and increases the viscosity of the mucus of the cervix. Depo-Provera in higher doses has an antitumor effect in hormone-sensitive malignant tumors. This effect is due, apparently, to the action on the receptors of steroid hormones and on the pituitary-gonadal system.

Additional and palliative treatment of recurrent and metastatic endometrial cancer or kidney cancer; palliative treatment for hormone-dependent forms of recurrent breast cancer in postmenopausal women.

Contraindications

Hypersensitivity to the components of the drug, pregnancy, lactation.

Dosage and administration

At endometrial cancer and kidney cancer the initial dose is 400-1000 mg per week in / m. If within a few weeks or months there is an improvement and stabilization of the process has been achieved, then maintenance therapy is prescribed at a dose of 400 mg per month.

In breast cancer the drug is prescribed i / m at the initial dose of 500 mg per day for 28 days. Then use maintenance doses - 500 mg 2 times a week. Treatment continues until signs of disease progression appear.

Immediately before use, the vial should be shaken well, so that the injected drug takes on the appearance of a homogeneous suspension.

Adverse reactions

Allergic reactions:anaphylaxis and anaphylactoid reactions, urticaria.

From the blood coagulation system: thromboembolism, thrombophlebitis.

From the side of the central nervous system: increased nervous irritability, insomnia, drowsiness, fatigue, depression, dizziness, headache.

Dermatologic: itching, rash, acne, hirsutism and alopecia.

From the reproductive system: dysfunctional uterine bleeding, bleeding from the genital tract, amenorrhea, decreased libido or anorgasmia, vaginitis, leucorrhea, hot flashes, lower abdominal pain, breast tenderness, galactorrhea.

Gastrointestinal: pain or discomfort in the stomach, nausea, flatulence.

Musculoskeletal system: cramps gastrocnemius muscles, pain in the back and joints.

Other: asthenia, hyperthermia, change in body weight and moon face.

Special notes

It is necessary to strictly observe the compliance of the used dosage form of the drug with indications for use.

Medroxyprogesterone should be used with extreme caution in patients with thrombophlebitis, thromboembolic complications, severe impaired liver function, and hypercalcemia.

Before using medroxyprogesterone for the treatment of gynecological diseases and contraception, it is necessary to exclude the presence in the patient of a tumor of the genitals or mammary glands.

When conducting histopathological studies of certain organs and tissues, it is necessary to warn the histologist about the previous treatment with progestogens. Against the background of the use of medroxyprogesterone, changes in the results of the following studies are possible: determination of the level of gonadotropins; determination of the level of Progesterone, cortisol, testosterone (in men), estrogen (in women) in the blood plasma; determination of the level of pregnandiol in the urine; carrying out test with sugar loading; Conducting a test with a metapiron.

Store at room temperature (20-25 ° C), out of the reach of children.